Cargando…
Severe synergistic toxicity from docetaxel in a patient treated concurrently with protease inhibitors as part of HIV post-exposure prophylaxis: a case report
INTRODUCTION: Docetaxel is a semisynthetic taxane commonly used in solid tumour oncology. Its pharmacokinetics has been widely studied, and it is well established that it is metabolized to pharmacologically inactive products by the cytochrome P450 3A iso-enzymes. However, there have been few reports...
Autores principales: | Hewish, Madeleine, Miller, Rowan, Forster, Martin, Smith, Ian |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827174/ http://dx.doi.org/10.4076/1752-1947-3-8866 |
Ejemplares similares
-
Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634
por: Atrafi, Florence, et al.
Publicado: (2021) -
Pre-exposure and Post-exposure Prophylaxis for Dog Bites
por: Joob, Beuy, et al.
Publicado: (2017) -
Secondary Prophylaxis of Docetaxel Induced Diarrhea with Loperamide: Case Report
por: Lee, Hee Yeon, et al.
Publicado: (2013) -
Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer
por: Sato, Kotaro, et al.
Publicado: (2019) -
Docetaxel-induced maculopathy possibly potentiated by concurrent hydroxychloroquine use
por: Elhusseiny, Abdelrahman M., et al.
Publicado: (2019)